162 related articles for article (PubMed ID: 12803319)
1. Immunological effects of thalidomide and its chemical and functional analogs.
Dredge K; Marriott JB; Dalgleish AG
Crit Rev Immunol; 2002; 22(5-6):425-37. PubMed ID: 12803319
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide derived immunomodulatory drugs (IMiDs) as potential therapeutic agents.
Marriott JB; Dredge K; Dalgleish AG
Curr Drug Targets Immune Endocr Metabol Disord; 2003 Sep; 3(3):181-6. PubMed ID: 12871024
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide: mechanisms of action.
Paravar T; Lee DJ
Int Rev Immunol; 2008; 27(3):111-35. PubMed ID: 18437602
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide analogs as emerging anti-cancer drugs.
Dredge K; Dalgleish AG; Marriott JB
Anticancer Drugs; 2003 Jun; 14(5):331-5. PubMed ID: 12782937
[TBL] [Abstract][Full Text] [Related]
5. Selective cytokine inhibitory drugs with enhanced antiangiogenic activity control tumor growth through vascular inhibition.
Gee MS; Makonnen S; al-Kofahi K; Roysam B; Payvandi F; Man HW; Muller GW; Lee WM
Cancer Res; 2003 Dec; 63(23):8073-8. PubMed ID: 14678955
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory effects of thalidomide analogs on LPS-induced plasma and hepatic cytokines in the rat.
Fernández-Martínez E; Morales-Ríos MS; Pérez-Alvarez V; Muriel P
Biochem Pharmacol; 2004 Oct; 68(7):1321-9. PubMed ID: 15345321
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide and lenalidomide in the treatment of multiple myeloma.
Kumar S; Rajkumar SV
Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621
[TBL] [Abstract][Full Text] [Related]
8. IMiDs: a novel class of immunomodulators.
Knight R
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S24-30. PubMed ID: 16085014
[TBL] [Abstract][Full Text] [Related]
9. Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
Anderson KC
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S3-8. PubMed ID: 16344099
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide for the treatment of multiple myeloma.
Hattori Y; Iguchi T
Congenit Anom (Kyoto); 2004 Sep; 44(3):125-36. PubMed ID: 15327481
[TBL] [Abstract][Full Text] [Related]
11. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma.
Raje N; Hideshima T; Anderson KC
Expert Rev Anticancer Ther; 2006 Sep; 6(9):1239-47. PubMed ID: 17020458
[TBL] [Abstract][Full Text] [Related]
13. The thalidomide saga.
Melchert M; List A
Int J Biochem Cell Biol; 2007; 39(7-8):1489-99. PubMed ID: 17369076
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide: a novel template for anticancer drugs.
Stirling D
Semin Oncol; 2001 Dec; 28(6):602-6. PubMed ID: 11740817
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis inhibitors derived from thalidomide.
Noguchi T; Fujimoto H; Sano H; Miyajima A; Miyachi H; Hashimoto Y
Bioorg Med Chem Lett; 2005 Dec; 15(24):5509-13. PubMed ID: 16183272
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapeutic and antitumour potential of thalidomide analogues.
Marriott JB; Muller G; Stirling D; Dalgleish AG
Expert Opin Biol Ther; 2001 Jul; 1(4):675-82. PubMed ID: 11727503
[TBL] [Abstract][Full Text] [Related]
17. Adverse effects of thalidomide administration in patients with neoplastic diseases.
Dimopoulos MA; Eleutherakis-Papaiakovou V
Am J Med; 2004 Oct; 117(7):508-15. PubMed ID: 15464708
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice.
Ng SS; MacPherson GR; Gütschow M; Eger K; Figg WD
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4192-7. PubMed ID: 15217957
[TBL] [Abstract][Full Text] [Related]
19. Thalidomid: current role in the treatment of non-plasma cell malignancies.
Kumar S; Witzig TE; Rajkumar SV
J Clin Oncol; 2004 Jun; 22(12):2477-88. PubMed ID: 15197211
[TBL] [Abstract][Full Text] [Related]
20. Recent advances of IMiDs in cancer therapy.
Li S; Gill N; Lentzsch S
Curr Opin Oncol; 2010 Nov; 22(6):579-85. PubMed ID: 20689431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]